Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Lamis K. Eldjerou"'
Autor:
Rajen Mody, Carl H June, Michael R Verneris, Stephan A Grupp, Keith J August, André Baruchel, Shannon L Maude, Peter Bader, Stella M Davies, John E Levine, Michael A Pulsipher, Andrew C Dietz, Susana Rives, G Douglas Myers, Jochen Buechner, Theodore W Laetsch, Henrique Bittencourt, Michael W Boyer, Barbara De Moerloose, Muna Qayed, Christine L Phillips, Timothy A Driscoll, Krysta Schlis, Patricia A Wood, Lan Yi, Mimi Leung, Lamis K Eldjerou
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Background Tisagenlecleucel, an anti-CD19 chimeric antigen receptor T cell therapy, has demonstrated efficacy in children and young adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) in two multicenter phase 2 trials (Clinica
Externí odkaz:
https://doaj.org/article/77ef91a4ad514631aed50eef2972200b
Autor:
Robert Zeiser, Christoph Schmid, Gheath Alatrash, Ron Ram, Yuan Wu, Hans-Jochen Jochen Weber, Stephanie Grzesiak, Lamis K. Eldjerou, Charles Craddock
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cd45a9ce86e52f3713d20a83e537026
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/99684
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/99684
Autor:
Karl S. Peggs, William Y. Go, Noelle V. Frey, Jennifer N. Brudno, Elena Mead, Bianca Santomasso, Rebecca Gardner, Steven Z. Pavletic, Marcelo C. Pasquini, Sattva S. Neelapu, Stephan A. Grupp, Kevin J. Curran, Frederick L. Locke, Daniel W. Lee, Cameron J. Turtle, Marcel R.M. van den Brink, Krishna V. Komanduri, Jae H. Park, Armin Ghobadi, Marcela V. Maus, John F. DiPersio, Lamis K. Eldjerou
Publikováno v:
Biology of Blood and Marrow Transplantation. 25:625-638
Chimeric antigen receptor (CAR) T cell therapy is rapidly emerging as one of the most promising therapies for hematologic malignancies. Two CAR T products were recently approved in the United States and Europe for the treatment ofpatients up to age 2
Autor:
Eytan M. Stein, Jörg Chromik, Cecilia Carpio, Rogier Mous, Jean-Jacques Kiladjian, Gheath Alatrash, Antonio Curti, Charles Craddock, Christoph Schmid, Robert Zeiser, Lamis K. Eldjerou, Hans-Jochen Jochen Weber, Claire Fabre, Jeffrey Scott, Daniel J. DeAngelo
Introduction: Siremadlin is an oral (PO), potent and selective 2 nd generation inhibitor of Murine Double Minute-2 (MDM2i), resulting in a p53-dependent anti-proliferative effect. Siremadlin has a well-characterized safety profile and encouraging sin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::34d98cac7ad0d712d98cb00b3f052808
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/98649
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/98649
Autor:
Patricia A. Wood, Susana Rives, Theodore W. Laetsch, Barbara De Moerloose, Lan Yi, Rakesh Awasthi, Lamis K. Eldjerou, Jochen Buechner, Hidefumi Hiramatsu, Gregory A. Yanik, David T. Teachey, Stephan A. Grupp, Andrea Chassot-Agostinho
Publikováno v:
Blood Adv
BLOOD ADVANCES
BLOOD ADVANCES
Cytokine release syndrome (CRS) is a systemic inflammatory response associated with chimeric antigen receptor T-cell (CAR-T) therapies. In severe cases, CRS can be associated with coagulopathy and hypofibrinogenemia. We present our global multicenter
Autor:
Stephan A. Grupp, Kazuto Natsume, Andrea Chassot Agostinho, Lamis K. Eldjerou, Katsutsugu Umeda, Hidefumi Hiramatsu, Kota Tokushige, Itaru Kato, Souichi Adachi, Yoko Watanabe
Publikováno v:
International journal of hematology. 111(2)
Tisagenlecleucel is an autologous T cell genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor. Here, we present the efficacy and safety of tisagenlecleucel in a subgroup of Japanese patients with rela
Autor:
Manisha Patel, Lamis K. Eldjerou, Stacie Ittershagen, Tetiana Taran, Charlene Hall, Florence Salmon, Deborah Roccoberton, Miriam Fuchs, Vadim V. Romanov, Oezlem Anak, Ali Shojaee, Solveig G. Ericson, Mimi Leung, David Lebwohl, Eric Bleickardt
Publikováno v:
Current hematologic malignancy reports. 14(1)
We describe the significant technological leap from bench to bedside that was achieved through a strong academic-industry collaboration between dedicated clinicians and researchers at the University of Pennsylvania, the Children’s Hospital of Phila
Autor:
Nicolas Boissel, Henrique Bittencourt, Peter Bader, André Baruchel, Hidefumi Hiramatsu, Christina Peters, Adriana Balduzzi, Jochen Buechner, Karen Thudium, Joerg Krueger, Marina White, Lamis K. Eldjerou, Susana Rives, Prasanthi Sanjeevi, Barbara De Moerloose
Publikováno v:
Journal of Clinical Oncology. 38:10518-10518
10518 Background: B2001X (NCT03123939) is a multicenter global study of tisa to provide access to patients (pts) with r/r ALL including prior anti-CD19 therapy after enrollment ended in the pivotal ELIANA (NCT02435849) study. We report clinical outco
Autor:
Florence Salmon, Lamis K. Eldjerou, Miriam Fuchs, Mayo Pujols, Matthew Robson, Christopher Acker, Jennifer Willert, Ranjan Tiwari, Lee Clough, Damien Howick
Publikováno v:
Blood. 134:5066-5066
The first and second authors contributed equally to this publication. Background: Tisagenlecleucel is a CD19-directed autologous chimeric antigen receptor (CAR)-T cell therapy approved for the treatment of patients (pts) up to 25 years of age with B-
Autor:
Koji Izutsu, Takanori Teshima, Marie José Kersten, Peter Borchmann, Joseph P. McGuirk, Ulrich Jaeger, Ranjan Tiwari, Koen van Besien, Harald Holte, Constantine S. Tam, Koji Kato, Stephen Ronan Foley, Edmund K. Waller, Jason R. Westin, Nina D. Wagner-Johnston, Richard T. Maziarz, Stephen J. Schuster, Rakesh Awasthi, Michael R. Bishop, P. Joy Ho, Stephan Mielke, Veronika Bachanova, Gilles Salles, Isabelle Fleury, Lamis K. Eldjerou, Paolo Corradini, Tomasz Lawniczek, John M. Magenau, Charalambos Andreadis, Samantha Jaglowski
Publikováno v:
Blood. 134:2883-2883
Background: Tisagenlecleucel is an autologous anti-CD19 chimeric antigen receptor (CAR)-T cell therapy that is approved for adult patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL). In the phase 2 JULIET trial, pts coul